[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PT772603E - Compostos substituidos de pirimidina e sua utilizacao - Google Patents

Compostos substituidos de pirimidina e sua utilizacao

Info

Publication number
PT772603E
PT772603E PT95926898T PT95926898T PT772603E PT 772603 E PT772603 E PT 772603E PT 95926898 T PT95926898 T PT 95926898T PT 95926898 T PT95926898 T PT 95926898T PT 772603 E PT772603 E PT 772603E
Authority
PT
Portugal
Prior art keywords
utilization
pyrimidine compounds
substituted pyrimidine
dopamine
compounds
Prior art date
Application number
PT95926898T
Other languages
English (en)
Inventor
Beate Hellendahl
Liliane Unger
Hans-Juergen Teschendorf
Rainer Munschauer
Annegret Lansky
Siegfried Bialojan
Karsten Wicke
Karla Drescher
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of PT772603E publication Critical patent/PT772603E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/38One sulfur atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56One oxygen atom and one sulfur atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60Three or more oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
PT95926898T 1994-07-15 1995-07-14 Compostos substituidos de pirimidina e sua utilizacao PT772603E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4425143A DE4425143A1 (de) 1994-07-15 1994-07-15 Substituierte Pyrimidinverbindungen und deren Verwendung

Publications (1)

Publication Number Publication Date
PT772603E true PT772603E (pt) 2002-11-29

Family

ID=6523322

Family Applications (1)

Application Number Title Priority Date Filing Date
PT95926898T PT772603E (pt) 1994-07-15 1995-07-14 Compostos substituidos de pirimidina e sua utilizacao

Country Status (23)

Country Link
US (2) US6342604B1 (pt)
EP (1) EP0772603B1 (pt)
JP (1) JP3819024B2 (pt)
KR (1) KR100395394B1 (pt)
CN (1) CN1124269C (pt)
AT (1) ATE219063T1 (pt)
AU (1) AU703857B2 (pt)
BG (1) BG63257B1 (pt)
CA (1) CA2195241A1 (pt)
CZ (1) CZ295346B6 (pt)
DE (2) DE4425143A1 (pt)
DK (1) DK0772603T3 (pt)
ES (1) ES2178676T3 (pt)
FI (1) FI970150A (pt)
HU (1) HUT77535A (pt)
IL (1) IL114599A (pt)
NO (1) NO312030B1 (pt)
NZ (1) NZ290389A (pt)
PT (1) PT772603E (pt)
SI (1) SI9520080B (pt)
TW (1) TW455587B (pt)
WO (1) WO1996002519A1 (pt)
ZA (1) ZA955868B (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19600934A1 (de) 1996-01-12 1997-07-17 Basf Ag Substituierte Aza- und Diazacycloheptan- und Cyclooctanverbindungen und deren Verwendung
DE19728996A1 (de) * 1997-07-07 1999-01-14 Basf Ag Triazolverbindungen und deren Verwendung
US6486162B2 (en) 1997-08-14 2002-11-26 Abbott Laboratories 2-{3-[4-(2-t-butyl-6-trifluoromethyl-4-pyrimidinyl)-1- piperazinyl] propylthio}-4-pyrimidinol fumarate
DE19735410A1 (de) 1997-08-14 1999-02-18 Basf Ag 2-{3-[4-(2-t-Butyl-6-trifluormethylpyrimidin-4-yl)piperazin-1-yl]propylmercapto}pyrimidin-4-ol-fumarat
US6632823B1 (en) * 1997-12-22 2003-10-14 Merck & Co., Inc. Substituted pyridine compounds useful as modulators of acetylcholine receptors
GB9810876D0 (en) 1998-05-20 1998-07-22 Smithkline Beecham Plc Compounds
PE20001088A1 (es) 1998-10-08 2000-12-02 Smithkline Beecham Plc Compuestos derivados de tetrahidrobenzazepina
DE19922443A1 (de) * 1999-05-07 2000-11-09 Basf Ag Verwendung von Dopamin-D3-Rezeptorliganden zur Herstellung von Arzneimittel für die Behandlung von Nierenfunktionsstörungen
EP1272187B1 (de) * 2000-03-27 2008-07-30 Abbott GmbH & Co. KG Dopamin-d3-rezeptor-liganden zur behandlung von sucht
DE10131543A1 (de) * 2001-06-29 2003-01-16 Abbott Lab Pyrimidinoxyalkylpiperazine und ihre therapeutische Verwendung
US7605259B2 (en) 2002-09-14 2009-10-20 University Of North Texas Health Science Center At Fort Worth Structurally rigid dopamine d3 receptor selective ligands and process for making them
DE10311065A1 (de) * 2003-03-13 2004-09-23 Abbott Gmbh & Co. Kg Pyrimidin-2-on-Verbindungen und ihre therapeutische Verwendung
US7320979B2 (en) * 2003-04-14 2008-01-22 Abbott Gmbh & Co. Kg. N-[(piperazinyl)hetaryl]arylsulfonamide compounds
US20040204422A1 (en) * 2003-04-14 2004-10-14 Abbott Gmbh & Co. Kg. N-[(Piperazinyl)hetaryl]arylsulfonamide compounds
DE10358004A1 (de) 2003-12-11 2005-07-14 Abbott Gmbh & Co. Kg Ketolactam-Verbindungen und ihre Verwendung
US20050137186A1 (en) 2003-12-18 2005-06-23 Abbott Gmbh & Co. Kg. Tetrahydrobenzazepines and their use
ATE529114T1 (de) 2003-12-18 2011-11-15 Abbott Gmbh & Co Kg Tetrahydrobenzazepine und ihre verwendung in der modulation des dopamin-d3-rezeptors
EP1591455A1 (en) * 2004-04-29 2005-11-02 Institut National De La Sante Et De La Recherche Medicale (Inserm) Essential tremor diagnostic and treatment
DE102004027358A1 (de) 2004-06-04 2005-12-29 Abbott Gmbh & Co. Kg Pyrimidinverbindungen und ihre Verwendung
DE102004027359A1 (de) 2004-06-04 2005-12-29 Abbott Gmbh & Co. Kg Pyridin-2-onverbindungen und deren Verwendung
MX2007001530A (es) * 2004-08-09 2007-04-23 Abbott Gmbh & Co Kg Compuestos de 4-piperazinil-pirimidina adecuados para tratar trastornos que responde a la modulacion del receptor dopamina d3.
JP4904277B2 (ja) * 2004-10-14 2012-03-28 アボット ゲーエムベーハー ウント カンパニー カーゲー ドーパミンd3受容体の調節に応答する障害の治療に好適な複素環化合物
DE102004061593A1 (de) 2004-12-21 2006-06-22 Abbott Gmbh & Co. Kg Substituierte N-heterocyclische Verbindungen und ihre therapeutische Verwendung
US7803441B2 (en) * 2005-06-17 2010-09-28 Eastman Chemical Company Intravenous components comprising polyester compositions formed from 2,2,4,4-tetramethyl-1,3-cyclobutanediol and 1,4-cyclohexanedimethanol
BRPI0709660A2 (pt) * 2006-04-03 2011-07-19 Glaxo Group Limided derivados de azabiciclo [3,1,0] hexila como moduladores dos receptores de dopamina d3
WO2007113260A1 (en) * 2006-04-03 2007-10-11 Glaxo Group Limited Azabicyclo [3. 1. o] hexyl derivatives as modulators of dopamine d3 receptors
GB0703387D0 (en) * 2007-02-21 2007-03-28 Glaxo Group Ltd Novel compounds
PA8802101A1 (es) 2007-11-02 2009-08-26 Abbott Gmbh & Co Kg Compuestos de 1,2,4-3,5-diona adecuados para el tratamiento de trastornos que responden a la modulación del receptor de dopamina d3
GB0908394D0 (en) 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
GB0913636D0 (en) 2009-08-05 2009-09-16 Univ Leuven Kath Novel viral replication inhibitors
KR20140003438A (ko) 2010-11-15 2014-01-09 카톨리에케 유니버시테이트 루벤 항바이러스성 축합 헤테로사이클릭 화합물
CN105541702B (zh) * 2016-01-27 2019-10-22 宜春学院 类卢扎朵仑结构的芳胺基烷基硫类化合物及其制备方法
WO2017181004A1 (en) * 2016-04-14 2017-10-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selective d3 dopamine receptor agonists and methods of their use

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1946472U (de) 1966-06-13 1966-09-22 Karl Schwarzwaelder Endstein der kotplate in stallboeden.
JPS4826777B1 (pt) 1969-08-18 1973-08-15
BE755015A (fr) * 1969-08-20 1971-02-01 Byk Gulden Lomberg Chem Fab Piperazinyl-alcoylamino-uraciles substitues par un groupe aryle, leurs ethers et thioethers, ainsi que leur procede de preparation
BE756127A (fr) 1969-09-12 1971-03-15 Hoechst Ag Ethers heterocycliques et leur preparation
GB1345449A (en) * 1971-05-14 1974-01-30 Science Union & Cie Pyridylpiperazines and process for their preparation
BE787126A (fr) * 1971-08-04 1973-02-05 Byk Gulden Lomberg Chem Fab Pyrimidines substituees, procedes de preparation de ces composes et medicaments contenant lesdits composes
BE787125A (fr) * 1971-08-04 1973-02-05 Byk Gulden Lomberg Chem Fab Pyrimidines substituees, leurs procedes de preparation et medicaments les contenant
BE792206A (pt) * 1971-12-02 1973-06-01 Byk Gulden Lomberg Chem Fab
CA985683A (en) * 1972-10-27 1976-03-16 Gilbert Regnier Procede de preparation de n-amidoethyl piperazines
GR66581B (pt) * 1978-02-21 1981-03-27 Delalande Sa
FR2539990A1 (fr) * 1983-01-28 1984-08-03 Sanofi Sa Composition pharmaceutique a action psychotrope dopaminergique contenant une 2-piperazinopyrimidine
DE3609596A1 (de) * 1986-03-21 1987-10-01 Hoechst Ag 2-azolylmethyl-2-aryl-1,3-dioxolane und deren salze, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung
DE3609598A1 (de) * 1986-03-21 1987-10-01 Hoechst Ag 2-azolylmethyl-2-aryl-1,3-dioxolane und deren salze, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung
FR2631625B1 (fr) * 1988-05-17 1992-10-16 Synthelabo Derives de phenyl-6 piperazinylalkyl-3 1h,3h-pyrimidinedione-2,4, leur preparation et leur application en therapeutique
DE3840289A1 (de) * 1988-11-30 1990-05-31 Merck Patent Gmbh Aminosaeurederivate
JP2814600B2 (ja) * 1989-08-31 1998-10-22 正幸 石川 排尿障害治療剤
FR2663638B2 (fr) 1990-04-06 1995-02-10 Institut Nal Sante Recherc Medic Polypeptides ayant une activite de recepteur dopaminergique, acides nucleiques codant pour ces polypeptides et utilisation de ces polypeptides pour le criblage de substances actives sur ces polypeptides.
JP2518965B2 (ja) 1990-09-21 1996-07-31 三井東圧化学株式会社 新規ピリジン誘導体及びそれを有効成分として含有する制癌剤効果増強剤
FR2668771B1 (fr) 1990-11-06 1995-03-17 Inst Nat Sante Rech Med Acides nucleiques codant pour des polypeptides ayant une activite de recepteur dopaminergique humain et utilisation de ces polypeptides pour le criblage de substances actives sur ces polypeptides.
FR2678272B1 (fr) * 1991-06-27 1994-01-14 Synthelabo Derives de 2-aminopyrimidine-4-carboxamide, leur preparation et leur application en therapeutique.
DK0577470T3 (da) * 1992-07-03 1995-10-02 Synthelabo 2-amino-N(((4-(aminocarbonyl)pyrimidin-2-yl)amino)alkyl) pyrimidin-4-carboxamid-derivater, deres fremstilling og deres anvendelse i terapi
FR2697253B1 (fr) * 1992-10-22 1994-12-02 Synthelabo Dérivés de 2-aminopyrimidine-4-carboxamide, leur préparation et leur application en thérapeutique.
RU2153494C2 (ru) * 1993-10-12 2000-07-27 Дзе Дюпон Мерк Фармасьютикал Компани 1-n-алкил-n-арилпиримидинамины, способ лечения заболеваний, фармацевтическая композиция
US5688795A (en) 1994-11-08 1997-11-18 Syntex (U.S.A.) Inc. 3-(4-phenylpiperazin-1-yl)propyl-amino, thio and oxy!-pyridine, pyrimidine and benzene derivatives as α1 -adrenoceptor antagonists
HUT76266A (en) * 1995-10-31 1997-07-28 Egyt Gyogyszervegyeszeti Gyar New piperazinyl-alkylthio-pyrimidine derivatives, pharmaceutical compositions containing them, and process for producing the active components

Also Published As

Publication number Publication date
CA2195241A1 (en) 1996-02-01
SI9520080B (sl) 2003-02-28
IL114599A0 (en) 1995-11-27
NO970162D0 (no) 1997-01-14
ZA955868B (en) 1997-01-14
NZ290389A (en) 1999-03-29
CN1124269C (zh) 2003-10-15
SI9520080A (sl) 1998-04-30
FI970150A0 (fi) 1997-01-14
HU9700113D0 (en) 1997-02-28
CZ12397A3 (en) 1997-08-13
KR970704702A (ko) 1997-09-06
JPH10502659A (ja) 1998-03-10
DK0772603T3 (da) 2002-07-15
US6444674B1 (en) 2002-09-03
US6342604B1 (en) 2002-01-29
IL114599A (en) 1999-08-17
NO970162L (no) 1997-03-14
EP0772603B1 (de) 2002-06-12
JP3819024B2 (ja) 2006-09-06
AU3111695A (en) 1996-02-16
BG63257B1 (bg) 2001-07-31
TW455587B (en) 2001-09-21
ATE219063T1 (de) 2002-06-15
BG101110A (en) 1997-08-29
EP0772603A1 (de) 1997-05-14
WO1996002519A1 (de) 1996-02-01
HUT77535A (hu) 1998-05-28
KR100395394B1 (ko) 2003-11-28
CN1152917A (zh) 1997-06-25
AU703857B2 (en) 1999-04-01
FI970150A (fi) 1997-01-14
DE4425143A1 (de) 1996-01-18
ES2178676T3 (es) 2003-01-01
NO312030B1 (no) 2002-03-04
CZ295346B6 (cs) 2005-07-13
DE59510244D1 (de) 2002-07-18

Similar Documents

Publication Publication Date Title
PT772603E (pt) Compostos substituidos de pirimidina e sua utilizacao
ES2196072T3 (es) Empleo de compuestos heterociclicos como ligandos de dopamina-d3.
NO20013443D0 (no) Triazolforbindelser med dopamin-D3-reseptoraktivitet
DE59510596D1 (de) Thiadiazolverbindungen als d3 dopaminrezeptorligand
FI970147A0 (fi) Triatsoliyhdisteitä ja niiden käyttö dopamiini-D3-ligandeina
SE9502921D0 (sv) New compounds
ATE231510T1 (de) Penamsulfone als beta-laktamase inhibitoren
MX9700125A (es) Compuestos de pirimidina.
MX9603722A (es) Nuevos pseudopeptidos sustituidos con heterociclos.